Research programme: inhibitors of peptide deformylase and Mur pathway enzymes - Novartis/Pfizer

Drug Profile

Research programme: inhibitors of peptide deformylase and Mur pathway enzymes - Novartis/Pfizer

Alternative Names: 415; LBM-415; NVP-PDF-713; PDF7; VIC-104959; VRC 3852; VRC-3324; VRC-3375; VRC-4307; VRC-4887

Latest Information Update: 13 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; Pfizer
  • Class Hydroxamic acids; Peptides
  • Mechanism of Action Cell wall inhibitors; Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Community-acquired pneumonia

Most Recent Events

  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 04 Mar 2005 Suspended - Phase-I for Community-acquired pneumonia in USA (unspecified route)
  • 16 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections antimicrobial activity, pharmacodynamics and pharmacokinetics section ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top